David F. Jarrard, MD close

David F. Jarrard, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.



University Hospital
(608) 263-4757 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship Urologic Oncology, The Johns Hopkins Hospital, Baltimore, MD
Residency University of Chicago Medical Center, Chicago, IL
Internship University of Chicago Medical Center, Chicago, IL
Medical School University of Virginia School of Medicine, Charlottesville, VA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.

PubMed Articles
Yu J Berthier E Craig A de Groot TE Sparks S Ingram PN Jarrard DF Huang W Beebe DJ Theberge AB Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling. Nat Biomed Eng . 2019 Aug 19;
[PubMed ID: 31427781]
Rutkowski DR Wells SA Johnson B Huang W Jarrard DF Lang JM Cho S Roldán-Alzate A Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. Am J Clin Exp Urol . 2019;7(4):215-222
[PubMed ID: 31511828]
Jarrard WE Schultz A Etheridge T Damodaran S Allen GO Jarrard D Yang B Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. PLoS One . 2019;14(6):e0218950
[PubMed ID: 31233548]
Damodaran S Lang JM Jarrard DF Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol . 2019 May;201(5):876-885
[PubMed ID: 30747897]
Wang JH Sierra P Richards KA Abel EJ Allen GO Downs TM Jarrard DF Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. BMC Urol . 2019 Apr 23;19(1):26
[PubMed ID: 31014300]
Etheridge T Liou JI Downs TM Abel EJ Jarrard DF Richards KA The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol . 2019 Apr;201(4):742-750
[PubMed ID: 30321553]
Anderson-Carter I Posielski N Liou JI Khemees TA Downs TM Abel EJ Jarrard DF Richards KA The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urol Oncol . 2019 Feb;37(2):130-137
[PubMed ID: 30528885]
Etheridge T Damodaran S Schultz A Richards KA Gawdzik J Yang B Cryns V Jarrard DF Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian J Urol . 2019 Jan;6(1):57-64
[PubMed ID: 30775249]
Richards KA Liou JI Cryns VL Downs TM Abel EJ Jarrard DF Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol . 2018 Dec;200(6):1256-1263
[PubMed ID: 29940252]
Etheridge T Straus J Ritter MA Jarrard DF Huang W Semen AMACR protein as a novel method for detecting prostate cancer. Urol Oncol . 2018 Dec;36(12):532.e1-532.e7
[PubMed ID: 30337219]
Spiniello M Knoener RA Steinbrink MI Yang B Cesnik AJ Buxton KE Scalf M Jarrard DF Smith LM HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein Interactomes. J Proteome Res . 2018 Sep 7;17(9):3022-3038
[PubMed ID: 29972301]
Maciolek KA Best SL Lopez V Posielski N Knoedler M Bushman WA Jarrard DF Downs TM Abel EJ Richards KA Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol . 2018 Aug;36(8):363.e13-363.e20
[PubMed ID: 29887242]
Etheridge T Liou J Downs TM Abel EJ Richards KA Jarrard DF The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. Am J Clin Exp Urol . 2018;6(3):123-132
[PubMed ID: 30038944]
Gravis G Boher JM Chen YH Liu G Fizazi K Carducci MA Oudard S Joly F Jarrard DM Soulie M Eisenberger MJ Habibian M Dreicer R Garcia JA Hussain MHM Kohli M Vogelzang NJ Picus J DiPaola R Sweeney C Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol . 2018 Jun;73(6):847-855
[PubMed ID: 29475737]
Cesnik AJ Yang B Truong A Etheridge T Spiniello M Steinbrink MI Shortreed MR Frey BL Jarrard DF Smith LM Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. Transl Oncol . 2018 Jun;11(3):808-814
[PubMed ID: 29723810]
Morgans AK Chen YH Sweeney CJ Jarrard DF Plimack ER Gartrell BA Carducci MA Hussain M Garcia JA Cella D DiPaola RS Patrick-Miller LJ Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol . 2018 Apr 10;36(11):1088-1095
[PubMed ID: 29522362]
Kyriakopoulos CE Chen YH Carducci MA Liu G Jarrard DF Hahn NM Shevrin DH Dreicer R Hussain M Eisenberger M Kohli M Plimack ER Vogelzang NJ Picus J Cooney MM Garcia JA DiPaola RS Sweeney CJ Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol . 2018 Apr 10;36(11):1080-1087
[PubMed ID: 29384722]
Sierra PS Damodaran S Jarrard D Clinical and pathologic factors predicting reclassification in active surveillance cohorts. Int Braz J Urol . 2018 Mar-Apr;44(3):440-451
[PubMed ID: 29368876]
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2018 Mar;36(3):88.e19-88.e25
[PubMed ID: 29169843]
Harshman LC Chen YH Liu G Carducci MA Jarrard D Dreicer R Hahn N Garcia JA Hussain M Shevrin D Eisenberger M Kohli M Plimack ER Cooney M Vogelzang NJ Picus J Dipaola R Sweeney CJ ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol . 2018 Feb 1;36(4):376-382
[PubMed ID: 29261442]